Cristal Therapeutics has announced the start of a collaboration with PX Biosolutions (Melbourne, Australia). The joint research and development is focussed on the application of Cristal Therapeutics’ vaccine technology CriVac for the design of innovative vaccines.
The CriVac platform enables the tailor-made development of well-characterized polymeric nanoparticles of a specific size, that allow optimal antigen presentation to dendritic cells. CriVac is one of the proprietary nanotechnology platforms of Cristal Therapeutics, next to CriPec.
PX Biosolutions is an Australian-based company operating from Melbourne, Victoria. PX Biosolutions’ scientists have developed DCtag vaccine formulations against various types of cancer. These vaccine formulations have been tested successfully in animal models.
Joost Holthuis, CEO of Cristal Therapeutics says: “We are very excited about this collaboration that fits our strategy to set up product developments with companies active in the vaccine area. We are convinced that we can create additional value for patients and vaccine companies by development of superior vaccine products based on our CriVac technology.”
Ann Meulemans, CEO of PX Biosolutions comments: “Our team is very enthusiastic about the possibility to enhance the flexibility of its DCtag platform by using the CriVac technology“.
